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BACKGROUND
Patients with chronic kidney disease have a high risk of adverse kidney and cardio-
vascular outcomes. The effect of dapagliflozin in patients with chronic kidney 
disease, with or without type 2 diabetes, is not known.
METHODS
We randomly assigned 4304 participants with an estimated glomerular filtration 
rate (GFR) of 25 to 75 ml per minute per 1.73 m2 of body-surface area and a uri-
nary albumin-to-creatinine ratio (with albumin measured in milligrams and cre-
atinine measured in grams) of 200 to 5000 to receive dapagliflozin (10 mg once 
daily) or placebo. The primary outcome was a composite of a sustained decline in 
the estimated GFR of at least 50%, end-stage kidney disease, or death from renal 
or cardiovascular causes.
RESULTS
The independent data monitoring committee recommended stopping the trial 
because of efficacy. Over a median of 2.4 years, a primary outcome event occurred 
in 197 of 2152 participants (9.2%) in the dapagliflozin group and 312 of 2152 par-
ticipants (14.5%) in the placebo group (hazard ratio, 0.61; 95% confidence interval 
[CI], 0.51 to 0.72; P<0.001; number needed to treat to prevent one primary outcome 
event, 19 [95% CI, 15 to 27]). The hazard ratio for the composite of a sustained 
decline in the estimated GFR of at least 50%, end-stage kidney disease, or death 
from renal causes was 0.56 (95% CI, 0.45 to 0.68; P<0.001), and the hazard ratio 
for the composite of death from cardiovascular causes or hospitalization for heart 
failure was 0.71 (95% CI, 0.55 to 0.92; P = 0.009). Death occurred in 101 participants 
(4.7%) in the dapagliflozin group and 146 participants (6.8%) in the placebo group 
(hazard ratio, 0.69; 95% CI, 0.53 to 0.88; P = 0.004). The effects of dapagliflozin 
were similar in participants with type 2 diabetes and in those without type 2 dia-
betes. The known safety profile of dapagliflozin was confirmed.
CONCLUSIONS
Among patients with chronic kidney disease, regardless of the presence or absence 
of diabetes, the risk of a composite of a sustained decline in the estimated GFR of 
at least 50%, end-stage kidney disease, or death from renal or cardiovascular causes 
was significantly lower with dapaglif lozin than with placebo. (Funded by Astra-
Zeneca; DAPA-CKD ClinicalTrials.gov number, NCT03036150.)
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Worldwide estimates indicate that nearly 700 million persons have chronic kidney disease.1 Chronic kid-
ney disease is an important contributor to illness 
and is associated with a diminished quality of 
life and a reduced life expectancy. Despite the 
widespread availability of simple laboratory tests 
to identify patients with impaired kidney func-
tion, fewer clinical trials have been conducted for 
kidney diseases than for other common medical 
conditions.2 Until recently, the only classes of 
medication that have been shown to slow a decline 
in kidney function were angiotensin-converting–
enzyme (ACE) inhibitors and angiotensin-recep-
tor blockers (ARBs); however, most of the evidence 
was generated in patients with type 2 diabetes.3-6
Sodium–glucose cotransporter 2 (SGLT2) in-
hibitors decrease glycated hemoglobin levels and 
have shown favorable effects on kidney and 
cardiovascular outcomes in large clinical trials 
involving patients with type 2 diabetes.7-9 The 
CREDENCE (Canagliflozin and Renal Events in 
Diabetes with Established Nephropathy Clinical 
Evaluation) trial showed that long-term adminis-
tration of canagliflozin conferred renal and car-
diovascular protection in patients with type 2 
diabetes with chronic kidney disease.10 Although 
the underlying mechanisms are not completely 
understood, the benefits of SGLT2 inhibitors ap-
pear to be independent of their blood glucose–
lowering effects and may be mediated by natri-
uresis and glucose-induced osmotic diuresis, 
leading to a reduction in intraglomerular pres-
sure.11-13 This favorable hemodynamic effect may 
also preserve kidney function in persons with 
kidney diseases due to causes other than type 2 
diabetes. We designed the Dapagliflozin and Pre-
vention of Adverse Outcomes in Chronic Kidney 
Disease (DAPA-CKD) trial to assess the long-
term efficacy and safety of the SGLT2 inhibitor 
dapagliflozin in patients with chronic kidney 
disease, with or without type 2 diabetes.
Me thods
Trial Design and Oversight
Our trial was a randomized, double-blind, pla-
cebo-controlled, multicenter clinical trial; details 
regarding the trial design and baseline charac-
teristics of the participants have been published 
previously.14,15 The trial was sponsored by Astra-
Zeneca and conducted at 386 sites in 21 coun-
tries from February 2, 2017, through June 12, 
2020. An executive committee consisting of nine 
academic members and two nonvoting employ-
ees of the sponsor was responsible for the de-
sign and oversight of the trial and the reporting 
of the results. The trial protocol (available with 
the full text of this article at NEJM.org) was ap-
proved by a central or local ethics committee at 
each trial site. All the participants provided writ-
ten informed consent before any trial-specific 
procedure commenced. The safety of the partici-
pants was overseen by an independent data 
monitoring committee. The analyses that were 
conducted by the sponsor were replicated by an 
independent academic group at the University 
Medical Center Groningen. The first draft of the 
manuscript was written by the first and last au-
thors and was revised by the coauthors. The deci-
sion to submit the manuscript for publication was 
made jointly by all the authors. The first and last 
authors vouch for the completeness and accuracy 
of the data and for the fidelity of the trial to the 
protocol.
Participants
Adults with or without type 2 diabetes who had 
an estimated glomerular filtration rate (GFR) of 
25 to 75 ml per minute per 1.73 m2 of body-sur-
face area and a urinary albumin-to-creatinine ratio 
(with albumin measured in milligrams and creati-
nine measured in grams) of 200 to 5000 were 
eligible for participation. All the participants 
were required to be receiving a stable dose of an 
ACE inhibitor or ARB for at least 4 weeks before 
screening. However, participants who were doc-
umented to be unable to take ACE inhibitors or 
ARBs were allowed to participate. Key exclusion 
criteria were a documented diagnosis of type 1 
diabetes, polycystic kidney disease, lupus ne-
phritis, or antineutrophil cytoplasmic antibody–
associated vasculitis. Participants who had re-
ceived immunotherapy for primary or secondary 
kidney disease within 6 months before enroll-
ment were also excluded. The full inclusion and 
exclusion criteria are listed in the Supplementary 
Appendix, available at NEJM.org.
Trial Procedures
Participants were randomly assigned to receive 
dapagliflozin (10 mg once daily) or matching pla-
cebo, in accordance with the sequestered, fixed-
randomization schedule, with the use of balanced 
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blocks to ensure an approximate 1:1 ratio of the 
two regimens. Randomization was stratified ac-
cording to the diagnosis of type 2 diabetes (yes 
or no) and the urinary albumin-to-creatinine ratio 
(≤1000 or >1000). Investigators used an interactive 
voice-response or Web-response system to deter-
mine trial-group assignments. Randomization 
was monitored to ensure that a minimum of 
30% of the participants were recruited to either 
the population with type 2 diabetes or the popu-
lation without diabetes. Recruitment of partici-
pants with an estimated GFR of 60 to 75 ml per 
minute per 1.73 m2 was halted on November 27, 
2017, to ensure that no more than 10% of the 
trial participants had stage 2 chronic kidney dis-
ease. Participants and all trial personnel (except 
the members of the independent data monitor-
ing committee) were unaware of the trial-group 
assignments. Dapagliflozin and placebo were 
packaged identically, with uniform tablet appear-
ance, labeling, and administration schedules.
After randomization, in-person trial visits were 
performed at 2 weeks, at 2, 4, and 8 months, and 
at 4-month intervals thereafter (Fig. S1 in the 
Supplementary Appendix). At each follow-up visit, 
vital signs were recorded, blood and urine sam-
ples were sent for laboratory assessment, and 
information on potential trial outcomes, adverse 
events, concomitant therapies, and adherence to 
the trial regimen was collected. Dapagliflozin or 
placebo was to be discontinued if pregnancy or 
diabetic ketoacidosis occurred. Before trial com-
pletion, each participant underwent a final trial 
visit.
Outcomes
The primary composite outcome, assessed in a 
time-to-event analysis, was the first occurrence of 
any of the following: a decline of at least 50% in 
the estimated GFR (confirmed by a second serum 
creatinine measurement after ≥28 days), the on-
set of end-stage kidney disease (defined as main-
tenance dialysis for ≥28 days, kidney transplan-
tation, or an estimated GFR of <15 ml per minute 
per 1.73 m2 confirmed by a second measurement 
after ≥28 days), or death from renal or cardio-
vascular causes. Secondary outcomes (also as-
sessed in time-to-event analyses) were, in hierar-
chical order, the composite kidney outcome of a 
sustained decline in the estimated GFR of at 
least 50%, end-stage kidney disease, or death from 
renal causes; a composite cardiovascular outcome 
defined as hospitalization for heart failure or 
death from cardiovascular causes; and death from 
any cause. An independent committee whose 
members were unaware of the trial-group assign-
ments adjudicated all primary and secondary 
outcomes, except for a sustained decline in the 
estimated GFR of at least 50% and a sustained 
estimated GFR of less than 15 ml per minute per 
1.73 m2, which were ascertained from central 
laboratory measurements. Members of the event-
adjudication committee and the outcome defini-
tions are reported in the Supplementary Appendix.
Selected adverse-event data were collected in 
the trial. These included serious adverse events, 
adverse events resulting in the discontinuation of 
dapagliflozin or placebo, and adverse events of 
interest (symptoms of volume depletion, renal 
events, major hypoglycemia, bone fractures, am-
putations, and potential diabetic ketoacidosis). 
Potential cases of diabetic ketoacidosis were adju-
dicated by the independent adjudication commit-
tee. All events suggestive of Fournier’s gangrene 
were evaluated by an internal safety group con-
sisting of representatives of the sponsor who were 
unaware of the trial-group assignments.
Statistical Analysis
The analytical approach and power calculations 
have been published previously,14 and the com-
plete prespecified statistical analysis plan is avail-
able with the protocol at NEJM.org. In brief, a 
formal interim analysis was originally planned 
when 75% of primary outcome events had oc-
curred. However, during the conduct of the trial it 
became apparent that the interim analysis would 
occur close to the end of the trial. The executive 
committee therefore decided to remove the in-
terim analysis from the protocol. We estimated 
that 681 primary outcome events would be 
needed to detect a 22% lower relative risk in the 
dapagliflozin group than in the placebo group 
(hazard ratio of 0.78), with 90% power using a 
two-sided alpha level of 0.05 and assuming an 
annual event rate for the primary outcome of 
7.5% in the placebo group. A closed testing pro-
cedure that included a prespecified hierarchical 
order of the primary and secondary outcomes 
was used to ensure control of type I error at a 
two-sided 0.05 level.
The primary efficacy analysis was based on 
the intention-to-treat population, which included 
all the participants who had undergone random-
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ization. A Cox proportional-hazards regression 
model that was stratified according to the fac-
tors used at randomization (type 2 diabetes and 
urinary albumin-to-creatinine ratio) and that 
was adjusted for the baseline estimated GFR was 
used to estimate the hazard ratio and 95% con-
fidence intervals for dapagliflozin as compared 
with placebo for the primary and secondary 
outcomes. Data were censored on April 3, 2020, 
or the date of the last central laboratory assess-
ment, clinical assessment, or known contact, 
depending on the specific outcome. Prespecified 
subgroups were assessed with the use of the 
same stratified Cox proportional-hazards model 
without adjustment for multiple comparisons. A 
mixed model for repeated measurements was 
used to analyze changes in the estimated GFR in 
the on-treatment analysis population. The model 
was adjusted for the baseline value, trial-group 
assignment, visit, and the interaction between 
trial-group assignment and visit. All available 
on-treatment measurements were used with no 
distinction made for missing outcomes for par-
ticipants who were alive and outcomes that were 
not observed because of death. The effect of 
dapagliflozin as compared with placebo on the 
rate of decline in the estimated GFR during the 
acute phase (baseline to week 2), chronic phase 
(week 2 until end of treatment), and total slope 
to month 30 was analyzed with the use of a two-
slope model; details are provided in the Supple-
mentary Appendix.
Safety data are summarized according to trial 
group with the use of the data set for all the 
participants who had undergone randomization 
and received at least one dose of dapagliflozin or 
placebo. Safety analyses were performed on all 
adverse events occurring before or at the trial 
closure visit. All analyses were performed with 
SAS software, version 9.4 (SAS Institute).
R esult s
Participants and Follow-up
From February 2017 through October 2018, a 
total of 7517 participants were screened, of whom 
4094 underwent randomization. Because of reg-
ulatory delays, enrollment in China did not com-
mence until December 2019, after which 210 
participants from China underwent randomiza-
tion until March 2020. Details about the random-
ization and follow-up of the participants are 
provided in Figure S2. The baseline characteris-
tics, including medications for type 2 diabetes 
and kidney disease, were balanced between the 
dapagliflozin and placebo groups (Table 1). The 
mean (±SD) age was 61.8±12.1 years, and 1425 
participants (33.1%) were female. The mean es-
timated GFR was 43.1±12.4 ml per minute per 
1.73 m2, the median urinary albumin-to-creati-
nine ratio was 949, and 2906 participants (67.5%) 
had received a diagnosis of type 2 diabetes.
After a regular review meeting on March 26, 
2020, the independent data monitoring commit-
tee recommended to the two coprincipal investi-
gators (the first and last authors) that the trial 
be discontinued because of clear efficacy, on the 
basis of 408 primary outcome events. The trial 
leadership team accepted this recommendation 
and chose April 3, 2020, as the cutoff date for all 
efficacy analyses.
At the conclusion of the trial, the median 
follow-up was 2.4 years (interquartile range, 
2.0 to 2.7). Dapaglif lozin was discontinued for 
reasons other than death in 274 participants, 
and placebo was discontinued in 309 partici-
pants (12.7% and 14.4%, respectively). In all, 
4289 participants (99.7%) completed the trial 
(i.e., were alive with follow-up data available at 
the trial completion visit or had died during fol-
low-up). A total of 11 participants (0.3%) with-
drew consent, and vital status was ascertained 
for all but 5 participants (0.1%).
Efficacy Outcomes
The primary composite outcome of a sustained 
decline in the estimated GFR of at least 50%, 
end-stage kidney disease, or death from renal or 
cardiovascular causes occurred in 197 partici-
pants (9.2%) in the dapagliflozin group and 312 
participants (14.5%) in the placebo group (hazard 
ratio, 0.61; 95% confidence interval [CI], 0.51 to 
0.72; P<0.001) (Table 2 and Fig. 1A). The event 
rates for all components of the composite out-
come favored dapagliflozin (Table 2). The num-
ber of participants who needed to be treated dur-
ing the trial period to prevent one primary outcome 
event was 19 (95% CI, 15 to 27).
The effect of dapagliflozin on the primary 
outcome was generally consistent across pre-
specified subgroups (Fig. 2). In participants with 
type 2 diabetes, the hazard ratio for the compari-
son of dapagliflozin and placebo for the primary 
outcome was 0.64 (95% CI, 0.52 to 0.79), as com-
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Age — yr 61.8±12.1 61.9±12.1
Female sex — no. (%) 709 (32.9) 716 (33.3)
Race — no. (%)†
White 1124 (52.2) 1166 (54.2)
Black 104 (4.8) 87 (4.0)
Asian 749 (34.8) 718 (33.4)
Other 175 (8.1) 181 (8.4)
Weight — kg 81.5±20.1 82.0±20.9
Body-mass index‡ 29.4±6.0 29.6±6.3
Current smoker — no. (%) 283 (13.2) 301 (14.0)




Mean — ml/min/1.73 m2 43.2±12.3 43.0±12.4
Distribution — no. (%)
≥60 ml/min/1.73 m2 234 (10.9) 220 (10.2)
45 to <60 ml/min/1.73 m2 646 (30.0) 682 (31.7)
30 to <45 ml/min/1.73 m2 979 (45.5) 919 (42.7)
<30 ml/min/1.73 m2 293 (13.6) 331 (15.4)
Hemoglobin — g/liter 128.6±18.1 127.9±18.0
Serum potassium — mEq/liter 4.6±0.5 4.6±0.6
Urinary albumin-to-creatinine ratio§
Median (interquartile range) 965 (472–1903) 934 (482–1868)
>1000 — no. (%) 1048 (48.7) 1031 (47.9)
Type 2 diabetes — no. (%) 1455 (67.6) 1451 (67.4)
Cardiovascular disease — no. (%)¶ 813 (37.8) 797 (37.0)
Heart failure — no. (%) 235 (10.9) 233 (10.8)
Previous medication — no. (%)
ACE inhibitor 673 (31.3) 681 (31.6)
ARB 1444 (67.1) 1426 (66.3)
Diuretic 928 (43.1) 954 (44.3)
Statin 1395 (64.8) 1399 (65.0)
*  Plus–minus values are mean ±SD. Percentages may not total 100 because of rounding. ACE denotes angiotensin-con-
verting enzyme, ARB angiotensin-receptor blocker, and GFR glomerular filtration rate.
†  Race was reported by the investigators; the designation “other” includes Native Hawaiian or other Pacific Islander, 
American Indian or Alaska Native, and other.
‡  The body-mass index is the weight in kilograms divided by the square of the height in meters.
§  The albumin-to-creatinine ratio was calculated with albumin measured in milligrams and creatinine measured in 
grams.
¶  Cardiovascular disease was defined as a history of peripheral artery disease, angina pectoris, myocardial infarction, per-
cutaneous coronary intervention, coronary-artery bypass grafting, heart failure, valvular heart disease, abdominal aorta 
aneurysm, atrial fibrillation, atrial flutter, ischemic stroke, transient ischemic attack, hemorrhagic stroke, carotid artery 
stenosis, cardiac-pacemaker insertion, vascular stent, coronary-artery stenosis, ventricular arrhythmia, implantable car-
dioverter–defibrillator, noncoronary revascularization, or surgical amputation.
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pared with 0.50 (95% CI, 0.35 to 0.72) in par-
ticipants without type 2 diabetes.
The incidence of each secondary outcome 
was lower in the dapagliflozin group than in the 
placebo group (Table 2). The hazard ratio for 
the kidney composite of a sustained decline in 
the estimated GFR of at least 50%, end-stage 
kidney disease, or death from renal causes was 
0.56 (95% CI, 0.45 to 0.68; P<0.001) (Table 2 and 
Fig. 1B). The hazard ratio for the composite of 
death from cardiovascular causes or hospitaliza-
tion for heart failure was 0.71 (95% CI, 0.55 to 
Figure 1. Primary and Secondary Outcomes.
The primary outcome was a composite of a sustained decline in the estimated glomerular filtration rate (GFR) of at least 50%, end-
stage kidney disease, or death from renal or cardiovascular causes (Panel A). The primary outcome and the secondary outcomes of a 
composite of a sustained decline in the estimated GFR of at least 50%, end-stage kidney disease, or death from renal causes (Panel B), 
a composite of death from cardiovascular causes or hospitalization for heart failure (Panel C), and death from any cause (Panel D) were 
estimated with the use of the Kaplan–Meier method. Hazard ratios, confidence intervals, and P values were estimated with the use of 
Cox proportional-hazards regression models, stratified according to randomization factors (diabetes diagnosis and urinary albumin-to-
creatinine ratio) and adjusted for baseline estimated GFR. Included in these analyses are all the participants who had undergone ran-
domization and received at least one dose of dapagliflozin or placebo. The graphs are truncated at 32 months (the point at which <15% 
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0.92; P = 0.009) (Table 2 and Fig. 1C). There were 
101 deaths (4.7%) from any cause in the dapa-
gliflozin group and 146 (6.8%) in the placebo 
group (hazard ratio, 0.69; 95% CI, 0.53 to 0.88; 
P = 0.004) (Table 2 and Fig. 1D).
The least-squares mean (±SE) estimated GFR 
slopes from baseline to 30 months in the dapa-
glif lozin and placebo groups were –2.86±0.11 
and –3.79±0.11 ml per minute per 1.73 m2 per year, 
respectively, resulting in a between-group differ-
ence of 0.93 ml per minute per 1.73 m2 per year 
(95% CI, 0.61 to 1.25) (Fig. 3). During the first 
2 weeks, there was a greater reduction in the 
estimated GFR in the dapagliflozin group than in 
the placebo group (–3.97±0.15 vs. –0.82±0.15 ml 
per minute per 1.73 m2). Thereafter, the annual 
change in the mean estimated GFR was smaller 
with dapagliflozin than with placebo (–1.67±0.11 
and –3.59±0.11 ml per minute per 1.73 m2, re-
spectively), for a between-group difference of 
1.92 ml per minute per 1.73 m2 per year (95% CI, 
1.61 to 2.24).
Figure 2. Primary Outcome According to Prespecified Subgroups at Baseline.
Shown are forest plots of the hazard ratios for the primary outcome (a composite of a sustained decline in the esti-
mated GFR of ≥50%, end-stage kidney disease, or death from renal or cardiovascular causes) according to prespeci-
fied baseline subgroups. Hazard ratios and confidence intervals were calculated with a Cox proportional-hazards 
model with stratification according to diabetes status and urinary albumin-to-creatinine ratio adjusted for baseline 
estimated GFR, with factors for trial group, subgroup, and the interaction between trial group and the subgroup 
variable. Race was reported by the investigators. The albumin-to-creatinine ratio was calculated with albumin mea-
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Safety Outcomes and Adverse Events
The incidences of adverse events and serious ad-
verse events were similar overall in the dapa-
glif lozin and placebo groups (Table 2). Diabetic 
ketoacidosis was not reported in any participants 
who received dapagliflozin and in two participants 
who received placebo. Neither diabetic ketoaci-
dosis nor severe hypoglycemia was observed in 
participants without type 2 diabetes. There was 
one confirmed case of Fournier’s gangrene in 
the placebo group and none in the dapagliflozin 
group.
Discussion
We found that participants with chronic kidney 
disease, with or without type 2 diabetes, who 
were randomly assigned to receive dapagliflozin 
had a lower risk of the primary composite outcome 
of a sustained decline in the estimated GFR of 
at least 50%, end-stage kidney disease, or death 
from renal or cardiovascular causes than partici-
pants who were assigned to receive placebo. Each 
of the components of the composite outcome oc-
curred less frequently in the dapagliflozin group, 
with results that were similar for the occurrence 
of death from cardiovascular causes or hospital-
ization for heart failure and death from any cause. 
Our trial adds to the literature by examining the 
effect of an SGLT2 inhibitor, added to background 
therapy including an ACE inhibitor or ARB, in 
participants with chronic kidney disease, with or 
without type 2 diabetes.
The kidney-protective effects of SGLT2 in-
hibitors have previously been shown in patients 
with type 2 diabetes and chronic kidney disease 
in the CREDENCE trial.10 In that trial, as in most 
previous cardiovascular outcome trials of SGLT2 
inhibitors, the lower estimated GFR cutoff for 
inclusion was 30 ml per minute per 1.73 m2.16 In 
contrast to the CREDENCE trial, the present 
trial examined the effects of an SGLT2 inhibitor 
in patients with chronic kidney disease of whom 
32.5% did not have type 2 diabetes and 14.5% 
had an estimated GFR below 30 ml per minute 
per 1.73 m2. Our trial confirms that the kidney-
protective effects of SGLT2 inhibitors extend to 
the broader population of persons with chronic 
kidney disease without type 2 diabetes, for whom 
ACE inhibitors are the only pharmacologic treat-
ments that have been shown to prevent kidney 
failure.3,4
Life expectancy is markedly reduced when 
kidney function declines or albuminuria devel-
Figure 3. Change from Baseline in Estimated GFR.
Shown is the least-squares mean change from baseline in the estimated GFR, calculated with the use of a repeated-
measures analysis including terms for trial group, baseline measurement, visit, and interaction between visit and 
trial group. The I bars indicate standard errors. The mean estimated GFR at baseline was 43.2 ml per minute per 
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ops. Global estimates indicate that 1.2 million 
deaths were attributable to chronic kidney dis-
ease in 2017.17 The findings from the present 
trial confirm the high mortality among patients 
with impaired kidney function. The markedly 
lower mortality in the dapagliflozin group than 
in the placebo group supports the use of dapa-
gliflozin as an addition to the therapeutic man-
agement of chronic kidney disease.
Participants in our trial also had a high risk 
of hospitalization for heart failure or death from 
cardiovascular causes. The lower risk of hospi-
talization for heart failure or death from cardio-
vascular causes in the dapagliflozin group than 
in the placebo group is consistent with the re-
sults of two previous trials of dapagliflozin, the 
DECLARE–TIMI 58 (Dapagliflozin Effect on 
Cardiovascular Events–Thrombolysis in Myocar-
dial Infarction 58) and DAPA-HF (Dapagliflozin 
and Prevention of Adverse Outcomes in Heart 
Failure) trials.9,18 Clinical trials of other SGLT2 
inhibitors have shown similar results.8,10,19
Dapagliflozin had an acceptable safety pro-
file in this population, which included partici-
pants with an estimated GFR as low as 25 ml 
per minute per 1.73 m2. Overall, the present 
trial confirmed the beneficial safety profile of 
dapagliflozin. In particular, there were no cases 
of diabetic ketoacidosis with dapagliflozin, and 
hypoglycemic episodes did not occur in partici-
pants without diabetes.
Our trial has some limitations. First, the trial 
was stopped on the basis of a recommendation 
from the independent data monitoring commit-
tee. This may have reduced the power of some 
secondary outcomes. However, the strong inter-
nal and external validity of the treatment effect 
suggests that this limitation is unlikely to have 
had a major influence on the findings. As in 
other trials of SGLT2 inhibitors, there was an 
initial dip in the estimated GFR, followed by a 
stabilization of kidney-function decline.7,8,10 This 
dip in the estimated GFR reflects favorable he-
modynamic changes in the glomerulus. We did not 
collect estimated GFR values after the completion 
of the trial and are unable to ascertain whether 
the initial dip in the estimated GFR is reversible 
after the discontinuation of dapagliflozin, as ob-
served in other dapagliflozin studies.20
The present trial showed that persons with 
chronic kidney disease who received dapagliflozin 
had a significantly lower risk of a composite of 
a sustained decline in the estimated GFR of at 
least 50%, end-stage kidney disease, or death 
from renal or cardiovascular causes than those 
who received placebo, independent of the pres-
ence or absence of type 2 diabetes. In addition, 
those who received dapagliflozin had a lower risk 
of death from cardiovascular causes or hospital-
ization for heart failure and had longer survival.
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